ArticleFrontiers in aging2025
The anti-aging potential of antihypertensive peptides of
Article in Frontiers in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Cellular senescence drives aging and disease by promoting inflammation and tissue dysfunction. The kidneys, highly susceptible to aging, worsen with hypertension, increasing chronic disease risk. Managing blood pressure with angiotensin-converting enzyme (ACE) inhibitors and natural bioactive peptides helps maintain kidney health. This study explores a kidney-associated aging network and algal peptides with renoprotective and anti-aging effects. Methods: Senescence-associated genes from Human Ageing Genomic Resources (HAGR) were used to construct and analyze a protein-protein interaction (PPI) network, refining a kidney-related subset ACE, angiotensin II Receptor Type 1 (AGTR1), and angiotensin II Receptor Type 2 (AGTR2). Algal antihypertensive peptides were filtered out of the laboratory dataset of algal peptides, Results: A senescence-associated PPI network revealed key aging-related proteins-IL1R, CD4, FN1, STAT3, CD45, APOE, CD44, ITGAM. CD8A, CD68, CDH1, ACE, AGTR1, and AGTR2-linked to inflammation, immunity, and fibrosis. Screening identified 54 antihypertensive peptides, among which seven were predicted to be non-allergenic and non-antigenic peptides, while six out of them exhibited anti-aging properties. KTFPY and others exhibited strong binding to ACE and kidney-aging proteins, suggesting therapeutic benefits. Discussion: The senescence-associated PPI network reveals potentially important aging-related proteins affecting kidney health. Algal peptides, particularly KTFPY, VYRT, PGDTY, PVAFN, and MTFF, exhibit strong ACE binding, suggesting potential antihypertensive and anti-aging benefits. CD68 expressed reliable binding affinities with small-molecule ACE inhibitors, and it indicated the repurposing potential of these drugs for aging-associated conditions. These computational results highlight the potential of peptide-based therapies in addressing age-related kidney dysfunction, and warrant further experimental investigations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.